Figure 2.

Ibrutinib or acalabrutinib attenuate the renal dysfunction caused by CLP-sepsis. Mice were randomly assigned to undergo CLP or sham surgery (n = 10). One hour later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h after CLP, blood samples were collected for analyses (n = 10 per group). (A) Serum urea (mmol/L). (B) Serum creatinine (μmol/L). All data are expressed as mean ± SEM for n number of observations. A value of ****P < 0.0001, ***P < 0.001, **P < 0.01 was considered to be statistically significant when compared to the control by one-way ANOVA followed by a Bonferroni's post-hoc test.